

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

Premium Sponsors



sanofi



Johnson & Johnson
Innovative Medicine

Standard Sponsors



UK Myeloma Society Autumn Day Incorporating Latest Developments into Clinical Practice – Diagnostics, Novel Therapies and MDT Dilemmas

Wednesday 11th November 2026

Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

Register to attend in person or watch a live stream

Joint Chairs: **Dr Jaimal Kothari** (Oxford University Hospitals)
Dr Sarah Lawless (Belfast City Hospital)

09.00 *Registration, coffee & exhibition*

09.25 Welcome and introduction

09.30 UK practice and access updates

Dr Ceri Bygrave
University Hospital of Wales

09.50 College of Myeloma UK - reflections on career and advocacy role

Dr Neil Rabin
University College London Hospitals

10.00 College of Myeloma UK - reflections on career and advocacy role

Professor Hermann Einsele
University Hospital Würzburg

10.10 Best of IMS 2026 - Glasgow

Dr Jennifer Travers
*Beatson West of Scotland Cancer Centre
Glasgow*

10.30 *Coffee & exhibition*

11.00 **IMS Abstracts and EHA Abstracts**

Exploring the epigenetic role of PRDM1: a target for IMiD-resistant multiple myeloma

Sophie Ball
*Imperial College Healthcare
UKMS/Binding Site EHA Bursary Winner*

Ambulatory delivery of bispecific antibodies in relapsed multiple myeloma (RRMM) via a virtual ward pathway: reduced inpatient bed-days and preserved safety

Veronica Lewis
*Addenbrooke's Hospital, Cambridge
UKMS/Menarini Stemline EHA Bursary Winner*

Whole proteome analysis of multiple myeloma patient samples provides new insights into IMiD/CELMOd resistance

Dr Sarah Bird
*Institute of Cancer Research, London
UKMS/Pfizer IMS Bursary Winner*

Physiological and quality-of-life trajectories during autologous transplantation: findings from the MY-TRAC study

Tommy Brown
*Royal Marsden Hospital, London
UKMS/Johson & Johnson IMS Bursary Winner*

Michael Morley Lecture

11.30 New developments in first line therapy

Dr Francesca Gay
University of Turin

12.20 *Lunch, networking & exhibition*

Parallel Sessions: Clinical and Scientific

UKMRA Science Forum

PORTLAND ROOM

In person attendance only. See next page for more information.

13.30 Speakers

14.30 Coffee break

15.00 Speakers

15.30 Networking and collaboration session

16.00 Summary and close

If you wish to attend this session, please ensure that you select the appropriate package when completing your registration.

Places are limited.

State of the Art Diagnostics

13.30 Identifying high risk patients

Dr Kevin Boyd
The Royal Marsden

13.50 Imaging role of WBMRI

Dr Gordon Cowell
*Queen Elizabeth University Hospital,
Glasgow*

14.10 The pros and cons of Pet/CT in multiple myeloma

Dr Shaheel Bhuv
Imperial College Healthcare

14.30 *Coffee break*

Sequencing Dilemmas

15.00 Sequencing immunotherapies

Professor Hermann Einsele
University Hospital Würzburg

Case 1: Choosing bispecific antibodies

Case 2: Managing patients post bispecifics/post BCMA

Case 3: Primary refractory/progression on DVRd

16.00 *Close*

Registration:

Standard Fee (until 28 October)
£80 (£55 for Scientists, Nurses & Pharmacists)

Late Fee (from 29 October)
£135 (£90 for Scientists, Nurses & Pharmacists)

Registration now open at www.collaborativeconferences.co.uk/ukmsociety

Online registration for this meeting is for healthcare professionals only

Please indicate if you wish to attend in person or watch the live stream while completing the registration form

Enquiries: Please contact Alex - alex@collaborativeconferences.co.uk

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

Premium Sponsors



sanofi



Johnson & Johnson
Innovative Medicine

Standard Sponsors



All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

UKMRA Science Forum at the UK Myeloma Society Autumn Day

Wednesday 11th November 2026

Cavendish Conference Centre - PORTLAND ROOM

Leading the Session:

Dr Shelly Lawson (Sheffield)

Dr Sarah Gooding (Oxford)

13.30	Pre-clinical evaluation of the CBP/p300 degrader CBPD-409 in multiple myeloma	Dr Mark Williams <i>Glasgow Caledonian University</i>
13.45	Pre-clinical evaluation of a dual action strategy to enhance myeloma therapy and prevent peripheral neuropathy	Dr Lisa Crawford <i>Queen's University Belfast</i>
14.00	BCMA-targeted MMAF therapy for multiple myeloma	Dr Zahraa Al-Amady <i>University of Sheffield</i>
14.15	Targeting Cks1b in myeloma	Dr Claire Seedhouse <i>University of Nottingham</i>
14.30	<i>Coffee break</i>	
15.00	Investigation of therapeutic vulnerabilities in high-risk myeloma and extramedullary disease	Prof Siobhan Glavey <i>Beaumont Hospital, Dublin</i>
15.15	Genome-scale maps of progression signatures for individual myeloma patients and candidate synthetic lethal vulnerabilities to overcome drug resistance	Dr Ian Overton <i>Queen's University Belfast</i>
15.30	Networking / collaboration session (speed networking)	
16.00	Summary and close	

Premium Sponsors



Standard Sponsors



All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.